Regenxbio (RGNX) Cost of Revenue (2014 - 2025)

Regenxbio's Cost of Revenue history runs 12 years deep, the most recent figure standing at $5.9 million for Q4 2025.

• On a quarterly basis, Cost of Revenue fell 6.17% year-over-year to $5.9 million in Q4 2025; TTM through Dec 2025 was $20.3 million, a 39.53% decrease from a year earlier, with the FY2025 full-year figure at $20.3 million, down 39.53% from the prior year.
• Cost of Revenue improved to $5.9 million in Q4 2025 per RGNX's latest filing, from $5.7 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $23.1 million in Q4 2021 and bottomed at $3.4 million in Q1 2025.
• The 5-year median for Cost of Revenue is $10.2 million (2021), against an average of $9.9 million.
• Across the five-year window, Cost of Revenue soared 224.0% in 2022 and slumped 73.84% in 2023, its largest moves.
• Year by year, Cost of Revenue stood at $23.1 million in 2021, then plunged by 44.56% to $12.8 million in 2022, then dropped by 12.09% to $11.2 million in 2023, then tumbled by 43.78% to $6.3 million in 2024, then decreased by 6.17% to $5.9 million in 2025.
• Per Business Quant, the three latest RGNX Cost of Revenue figures stand at $5.9 million (Q4 2025), $5.7 million (Q3 2025), and $5.2 million (Q2 2025).